Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
worldwide. Currently, the routinely used modalities are unable to adequately determine the …

Staging of liver fibrosis and diagnosis, or exclusion, of early compensated liver cirrhosis are
important in the treatment decisions and surveillance of patients with chronic liver disease …

Aims The Korean Association for the Study of the Liver (KASL) Practice Guidelines for
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver pathologies characterized by
hepatic steatosis with a history of little to no alcohol consumption or secondary causes of …

Background & Aims There is an unmet need for the non-invasive monitoring of fibrosis
progression in patients with autoimmune hepatitis (AIH). The aim of this study was to assess …

Liver fibrosis reflects sustained liver injury often from multiple, simultaneous factors. Whilst
the presence of mild fibrosis on biopsy can be a reassuring finding, the identification of …

Chronic liver disease is a major cause of morbidity and mortality worldwide and usually
develops over many years, as a result of chronic inflammation and scarring, resulting in end …

Independent of their etiology, all chronic liver diseases ultimately lead to liver cirrhosis,
which is a major health problem worldwide. The underlying molecular mechanisms are still …

Transient elastography (TE) is a reliable tool for the non-invasive assessment of liver fibrosis
in routine clinical practice. TE is currently approved for use in Europe, Asia and the United …

Tissue engineering and cell based liver therapies have utilized primary hepatocytes with
limited success due to the failure of hepatocytes to maintain their phenotype in vitro. In order …